Zobrazeno 1 - 10
of 4 959
pro vyhledávání: '"DABRAFENIB"'
Autor:
Gal Rubinstein, Benjamin Izar, Diana E. McDonnell, Andrea Fernandez Valledor, Justin A. Fried, Kevin Clerkin, Edward F. Lin, Dor Lotan, Farhana Latif, Gabriel Sayer, Nir Uriel, Jayant K. Raikhelkar
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-4 (2024)
Abstract Background Cancer survivors (CS) comprise a particularly high-risk group for both de-novo and recurrent malignancies after solid organ transplantation. Case presentation We report a case of relapsed melanoma, presented as metastatic disease
Externí odkaz:
https://doaj.org/article/0d335aeb221c4937a728f4e1b0d66e9a
Autor:
Qi Wang, Chunyu Zhang, Ying Pang, Meng Cheng, Rui Wang, Xu Chen, Tongjie Ji, Yuntong Yang, Jing Zhang, Chunlong Zhong
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background As part of stress-triggered molecules, immediate early response 3 (IER3) dysregulation has been reported to sustain pro-oncogenic pathways and precede malignant transformation. However, the role of IER3 in glioma pathology is ill-
Externí odkaz:
https://doaj.org/article/4b716bea1cb94f2a8c5dfa0131456363
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Papillary craniopharyngiomas are rare tumors prevalent to the precision oncology world due to their high rate of BRAF V600E mutations. Symptoms include vision loss, neuroendocrine dysfunction, and cognitive dysfunction. Treatment involves an interdis
Externí odkaz:
https://doaj.org/article/b4a741bb71e247abb31e82558ed854ab
Autor:
Kensuke Namba, Kazutoshi Isobe, Hiroki Wakabayashi, Ryogo Ohashi, Hiromasa Sakurai, Daiki Sakai, Yusuke Irie, Kenta Takashima, Yu Murakami, Kaichi Kaneko, Nobuyuki Hiruta, Yasuo Matsuzawa
Publikováno v:
Respirology Case Reports, Vol 12, Iss 10, Pp n/a-n/a (2024)
Abstract BRAF is a mediator that activates the mitogen‐activated protein kinase pathway. A mutation in BRAF can cause abnormal pathway activation, leading to cell proliferation. In a Phase II study, the combination therapy of the BRAF inhibitor dab
Externí odkaz:
https://doaj.org/article/9dcef2518b7a436daccff34d260194dd
Autor:
Rambabu Vasamsetti, Naresh Babu Gatchakayala, P. Vijaya Kumar, Ch. Praveen, S.V.G.V.A Prasad, Bandaru Madhav
Publikováno v:
Results in Chemistry, Vol 11, Iss , Pp 101823- (2024)
We have design and synthesized a new series of 1,2,4-oxadiazole incorporated thieno[2,3-d]thiazole-isoxazole-pyridine analogues (13a-j) and were confirmed by 1H NMR, 13C NMR and mass spectral data. Further, the newly synthesized compounds (13a–j) w
Externí odkaz:
https://doaj.org/article/a8fcfde9467a4b3e8766ddb4087a80fa
Autor:
Afrodité Németh, Gréta L. Bányai, Nikolett K. Dobos, Tamás Kós, Anikó Gaál, Zoltán Varga, Edit I. Buzás, Delaram Khamari, Magdolna Dank, István Takács, A. Marcell Szász, Tamás Garay
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Extracellular vesicles (EVs) constitute a vital component of intercellular communication, exerting significant influence on metastasis formation and drug resistance mechanisms. Malignant melanoma (MM) is one of the deadliest forms of skin ca
Externí odkaz:
https://doaj.org/article/82cfcaeb75a74849a5be0051bae737b3
Autor:
Weisong Li, Chao Zheng, Xi Xu, Yujie Xia, Kai Zhang, Ao Huang, Xinyu Zhang, Yong Zheng, Guofang Chen, Shuyong Zhang
Publikováno v:
Cellular & Molecular Biology Letters, Vol 29, Iss 1, Pp 1-23 (2024)
Abstract Background Melanoma is the most lethal skin cancer characterized by its high metastatic potential. In the past decade, targeted and immunotherapy have brought revolutionary survival benefits to patients with advanced and metastatic melanoma,
Externí odkaz:
https://doaj.org/article/51d85e3ddbff48978114870473f9f037
Autor:
Takako Inoue, Kei Kunimasa, Motohiro Tamiya, Takahisa Kawamura, Toshiyuki Minami, Kazumi Nishino
Publikováno v:
Thoracic Cancer, Vol 15, Iss 11, Pp 929-933 (2024)
Abstract We present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved a remarkable long‐term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progre
Externí odkaz:
https://doaj.org/article/8d66f6c5b4744281b900c0ad4f7f6b80
BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country
Autor:
Dima Abu Laban, Abeer Alsharif, Maysa Al-Hussaini, Mouness Obeidat, Bayan Maraqa, Qasem Alzoubi, Awni Musharbash, Saad Jaddoua, Raed Ramlawi, Kawther Khaleifeh, Ahmad Kh. Ibrahimi, Nasim Sarhan, Eric Bouffet, Nisreen Amayiri
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionMost pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income
Externí odkaz:
https://doaj.org/article/a23babfb377e407680f20d2e4d1da559
Autor:
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Shigeki Nanjo, Seiji Yano, Keishi Mizuguchi, Hiroko Ikeda, Shinji Takeuchi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
We report a case of limited effectiveness of dabrafenib and trametinib in a 59-year-old man with poorly differentiated lung carcinoma and a rare BRAF K601E mutation. The patient, unresponsive to chemotherapy and immunotherapy, received these targeted
Externí odkaz:
https://doaj.org/article/67c78e62172b42b580e93f5cade774a9